July 2019 Issue of The Medicine Maker

The uncertainty surrounding the UK’s future with Europe is having a measurable effect on pharma. But it looks like the end is nowhere in sight.

At the helm of SkinBioTherapeutics, Catherine O’Neill and her team are exploring the ways in which probiotic bacteria can be used topically.

Can artificial approaches trump the conventions of traditional organic synthesis for the production of raw pharmaceutical products within cells?

The game “Tumor Quest” seeks to improve people’s understanding of cancer.

Scouting for new leadership, prices hikes and successful acquisitions. What’s new for pharma in business?

The FDA has accepted TraceLink's blockchain and digital recall projects into its DSCSA Pilot Program.

How do we battle gut bacteria that reduce medicine efficacy?

What are the consequences of allowing patients to purchase cell and gene therapies directly from hospitals?

Scientific careers are inherently unpredictable, but there are a number of steps we can take to be prepared.

Qualitative risk assessments are a great way to approach quality management and train your operators at the same time.

Drug repurposing is in vogue, but it’s not always as easy as you think.

Sam Herbert walks us through the past 50 years of pharma logistics.

With many APIs exhibiting a strong, bitter taste, taste-masking is essential, particularly for pediatric patients.

Will antibody drug conjugates live up to the ever-growing expectations surrounding them?

Orphan drugs for rare diseases represent a significant unmet medical need for pharma, but commercialication can be tricky...

With a no-deal Brexit still a real possibility, Merck continues to prepare for the worst case scenario.

Biopharma manufacturers have been using the same assays for viral safety testing for decades.

Claudia Zylberberg reveals her career lessons learned and offers her perspective on the now booming advanced therapies industry.

We sit down with Nigel Theobald, Chief Executive, N4 Pharma. He tells us the story of his career and offers some advice for budding entrepreneurs.